Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers
Journal of Medicinal Chemistry · 13.08.2026 · 69 (15) · 18838-18855
DOI: 10.1021/acs.jmedchem.6c01115 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 30.07.2026. Verfasst von Lijie Lin und 12 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing210023, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Purine-Nucleoside Phosphorylase, Methionine Adenosyltransferase, Enzyme Inhibitors. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Shanghai Institute of Materia Medica, Chinese Academy of Sciences, National Science and Technology Major Project.
Abstract (Originalsprache)
Targeting methionine adenosyltransferase 2A (MAT2A) represents an attractive synthetic lethal approach for treating methylthioadenosine phosphorylase (MTAP)-deleted cancers. Despite promising progress in the development of MAT2A inhibitors, many reported compounds remain limited by insufficient selectivity, systemic toxicity, and the stereochemical complexities of atropisomerism. Through structure-guided optimization of our previously reported atropisomeric lead, we identified ZS97 (26), a potent MAT2A inhibitor that lacks axial chirality. The nonatropisomeric nature simplifies pharmacological development by avoiding the need for asymmetric synthesis or chiral resolution. ZS97 demonstrated potent enzymatic inhibition, effectively depleting intracellular SAM and suppressing downstream PRMT5-mediated methylation. This biochemical blockade selectively triggered the DNA damage response and cell growth inhibition in MTAP-deficient cancer cells. Furthermore, ZS97 exhibited favorable oral bioavailability and induced significant tumor inhibition in an NCI-H838 xenograft model without associated weight loss. These findings highlight ZS97 as a structurally optimized orally active candidate with therapeutic potential for MTAP-deficient cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- School of Chinese Materia Medica, Nanjing University of Chinese Medicine, Nanjing210023, China.
- Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
- Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai201203, China.
- University of Chinese Academy of Sciences, Beijing100049, China.
- School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou310024, China.
ORCID-Profile: Xiaomin Luo, Sulin Zhang, Mingyue Zheng, Shilin Xu
Förderung
- Shanghai Institute of Materia Medica, Chinese Academy of Sciences
- National Science and Technology Major Project
Zitieren
APA
Lin, L., Xie, Z., Liu, J., Fan, Z., Shi, Z., Sun, Y., Lin, K., Cui, R., Jiang, X., Luo, X., Zhang, S., Zheng, M., & Xu, S. (2026). Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers. Journal of Medicinal Chemistry, 69(15), 18838-18855. https://doi.org/10.1021/acs.jmedchem.6c01115
Vancouver
Lin L, Xie Z, Liu J, Fan Z, Shi Z, Sun Y, et al. Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers. Journal of Medicinal Chemistry. 2026;69(15):18838-18855. doi:10.1021/acs.jmedchem.6c01115
BibTeX
@article{Lin2026,
author = {Lin, Lijie and Xie, Zhiyin and Liu, Jiayue and Fan, Zhehuan and Shi, Zihan and Sun, Yaoliang and Lin, Kexin and Cui, Rongrong and Jiang, Xinyu and Luo, Xiaomin and Zhang, Sulin and Zheng, Mingyue and Xu, Shilin},
title = {Discovery of a Potent, Selective, and Orally Bioavailable Achiral MAT2A Inhibitor for Treating MTAP-Deficient Cancers},
journal = {Journal of Medicinal Chemistry},
year = {2026},
volume = {69},
number = {15},
pages = {18838--18855},
doi = {10.1021/acs.jmedchem.6c01115}
}
EUVIMED